EPISODE · Apr 18, 2024 · 12 MIN
Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: the STEP-HFpEF and STEP-HFpEF DM randomised trials - report from ACC2024
from Medical Digest & Congress Report · host Medical Congress News
Professor Mikhail Kosiborod shared his insights onthe STEP-HFpEF and STEP-HFpEF DM randomised trials. Discussed studies: - Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials - Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes Video: https://medicaldigest.org/scientific-contents/interview:semaglutide-versus-placebo-people-obesity-related-heart-failure-preserved-ejection-fraction-step-hfpef-and-step-hfpef-dm-randomised-trials
Embed this episode
NOW PLAYING
Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: the STEP-HFpEF and STEP-HFpEF DM randomised trials - report from ACC2024
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.